Impact of Drugs on Diabetes Risk and Glycemic Control

  • Simona FrontoniEmail author
  • Fabiana Picconi
Reference work entry
Part of the Endocrinology book series (ENDOCR)


A variety of pharmacological agents affect glucose homeostasis resulting in hyperglycemia, thus predisposing to or precipitating diabetes, when pre-existing risk factors are present. Drug-induced hyperglycemia is often benign and reversible within days with some drugs but may take longer if it is secondary to weight gain or peripheral insulin resistance. Drug-induced hyperglycemia can also implicate an increased risk of microvascular and macrovascular complications, infections, metabolic coma, and even death.

Patients showing factors predisposing to the development of diabetes mellitus (sedentary lifestyle, overweight or obesity, impaired fasting glucose or glucose intolerance, family history of diabetes, history of vascular disease, gestational diabetes, or at least one risk factor for metabolic syndrome) are at particular risk of drug-induced hyperglycemia, as some drugs can worsen pre-existing insulin resistance or pancreatic dysfunction. Thus, these risk factors should be considered before initiating drugs with potentially disturbing effects on glycemic control; moreover, efforts should be made to identify and closely monitor patients receiving drugs that are known to induce hyperglycemia. Possible mechanisms of drug-induced hyperglycemia include alterations of insulin secretion and sensitivity, direct cytotoxic effects on pancreatic cells, and increase in glucose production. Several potential strategies may be used to counteract hyperglycemia, first of all lifestyle intervention, but also a dose reduction, particularly for agents that exhibit a dose-dependent effect on glycemia. However, the discontinuation of the incriminated drug, when possible, is the best option to reverse drug-induced hyperglycemia. The time needed to improve or return to baseline glycemia generally depends on the offending drug.


Drug-related diabetes 


  1. Ahmad S. Nicardipine-induced hyperglycemia. Am Fam Physician. 1992;45(2):449–52. Sharma SN, Iyengar SS, Hegde KP. Nifedipine induced hyperglycaemia. J Assoc Physicians India 1990;38(9):673–4.PubMedGoogle Scholar
  2. Aksnes TA, Kjeldsen SE, Mancia G. The effect of antihypertensive agents on new-onset diabetes mellitus: time to amend the guidelines? Am J Cardiovasc Drugs. 2006;6:139–47.PubMedCrossRefGoogle Scholar
  3. Albrecht H, Stellbrink HJ, Arastéh K. Didanosine-induced disorders of glucose tolerance. Ann Intern Med. 1993;119(10):1050.PubMedCrossRefGoogle Scholar
  4. Alderman MH. New onset diabetes during antihypertensive therapy. Am J Hypertens. 2008;21(5):493–9.PubMedCrossRefGoogle Scholar
  5. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Drug-Induced Hyperglycaemia and Diabetes Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.CrossRefGoogle Scholar
  6. Al-Rubeaan K, Ryan EA. Phenytoin-induced insulin insensitivity. Diabet Med. 1991;8:968–70.PubMedCrossRefGoogle Scholar
  7. American Diabetes Association. Position statement: standards of medical care in diabetes. Diabetes Care. 2011;34:S11–61.PubMedCentralCrossRefPubMedGoogle Scholar
  8. American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38:S1–S93. Scholar
  9. Amorim S, Dias P, Rocha G, et al. Poisoning with calcium channel blockers – a case report and review of the literature. Rev Port Cardiol. 2001;20(12):1249–57.PubMedGoogle Scholar
  10. Andersohn F, Schade R, Suissa S, et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009;166:591–8.PubMedCrossRefPubMedCentralGoogle Scholar
  11. Anonymous. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet. 1981;2:539–43.Google Scholar
  12. Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychiatry. 2003;64:22–9.PubMedPubMedCentralGoogle Scholar
  13. Atlan-Gepner C, Bouabdallah R, Valero R, et al. A cyclophosphamide-induced autoimmune diabetes. Lancet. 1998;352(9125):373–4.PubMedCrossRefPubMedCentralGoogle Scholar
  14. Ayers K, Byrne LM, DeMatteo A, et al. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension. 2012;59:893–8.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Ayvaz G, Balos Törüner F, Karakoc A, et al. Acute and chronic effects of different concentrations of free fatty acids on the insulin secreting function of islets. Diabete Metab. 2002;28:3S7–12.PubMedPubMedCentralGoogle Scholar
  16. Bakris GL, Fonseca V, Katholi RE, GEMINI Investigators, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227–36.CrossRefGoogle Scholar
  17. Bangalore S, Parkar S, Grossman E, et al. A metaanalysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007;100(8):1254–62.PubMedCrossRefPubMedCentralGoogle Scholar
  18. Baptista T, Lacruz A, de Mendoza S, et al. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry. 2000;33:81–8.PubMedCrossRefPubMedCentralGoogle Scholar
  19. Batra YK, Rajeev S, Samra T, et al. Octreotide-induced severe paradoxical hyperglycemia and bradycardia during subtotal pancreatectomy for congenital hyperinsulinism in an infant. Paediatr Anaesth. 2007;17(11):1117–9.PubMedCrossRefPubMedCentralGoogle Scholar
  20. Belcastro V, D’Egidio C, Striano P, et al. Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res. 2013;107(1–2):1–8. Scholar
  21. Benton CB, Thomas DA, Yang H, et al. Safety and clinical activity of 5-aza-20- deoxycytidine (decitabine) with or without hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014;167:356–65.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Bhattacharya R, Ajmera M, Bhattacharjee B. Use of antidepressants and statins and short-term risk of new-onset diabetes among high risk adults. Diabetes Res Clin Pract. 2014;105:251–60. Scholar
  23. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med. 2002;17:717–20.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Bollen M, Keppens S, Stalmans W. Specific features of glycogen metabolism in the liver. Biochem J. 1998;336(Pt 1):19–31.PubMedPubMedCentralCrossRefGoogle Scholar
  25. Boots JM, van Duijnhoven EM, Christiaans MH, et al. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol. 2002;13:221–7.PubMedPubMedCentralGoogle Scholar
  26. Boudreaux JP, McHugh L, Canafax DM, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation. 1987;44(3):376–81.PubMedCrossRefPubMedCentralGoogle Scholar
  27. Brault M, Ray J, Gomez Y, et al. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism. 2014;63:735–45.PubMedCrossRefPubMedCentralGoogle Scholar
  28. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium channel blocker or diuretic in the International Nifedipine GITS study: intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366–72.PubMedCrossRefPubMedCentralGoogle Scholar
  29. Brown MJ, Williams B, Morant SV, British Hypertension Society’s Prevention, Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group, et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016;4(2):136–47.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Burt MG, Willenberg VM, Petersons CJ, et al. Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: a cross-sectional study. Rheumatology (Oxford). 2012;51(6):1112–9.CrossRefGoogle Scholar
  31. Capeau J, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS. 2012;26(3):303–14. Scholar
  32. Carter BL, Einhorn PT, Brands M. Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension. 2008;52:30–6.CrossRefGoogle Scholar
  33. Chang AM, Smith MJ, Galecki AT, Bloem CJ, Halter JB. Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance. J Clin Endocrinol Metab. 2006;91(9):3303–9.PubMedCrossRefPubMedCentralGoogle Scholar
  34. Ciombor KK, Feng Y, Benson AB 3rd, et al. Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Investig New Drugs. 2014;32:1017–27.CrossRefGoogle Scholar
  35. Cooper-DeHoff RM, Wen S, Beitelshees AL, et al. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension. 2010;55:61–8.PubMedCrossRefPubMedCentralGoogle Scholar
  36. Correll CU, Detraux J, De Lepeleire J, et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14:119–36.PubMedPubMedCentralCrossRefGoogle Scholar
  37. Coyle P, Carr AD, Depczynski BB, et al. Diabetes mellitus associated with pentamidine use in HIV-infected patients. Med J Aust. 1996;165:587–8.PubMedPubMedCentralGoogle Scholar
  38. Crook D, Godsland I. Safety evaluation of modern oral contraceptives: effects on lipoprotein and carbohydrate metabolism. Contraception. 1998;57:189–201.PubMedCrossRefPubMedCentralGoogle Scholar
  39. Crouthamel MC, Kahana JA, Korenchuk S, et al. Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res. 2009;15(1):217–25.PubMedCrossRefPubMedCentralGoogle Scholar
  40. Dahlöf B, Devereux RB, Kjeldsen SE, LIFE Study Group, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995–1003.PubMedCrossRefPubMedCentralGoogle Scholar
  41. Demyttenaere K, Jaspers L. Review: bupropion and SSRI-induced side effects. Psychopharmacology. 2008;22:792–804.CrossRefGoogle Scholar
  42. Deng C. Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol Metab Clin N Am. 2013;42:545–63.CrossRefGoogle Scholar
  43. Depczynski B, Daly B, Campbell LV, et al. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabet Med. 2000;17(1):15–9.PubMedCrossRefPubMedCentralGoogle Scholar
  44. Derijks HJ, Meyboom RH, Heerdink ER, et al. The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. Eur J Clin Pharmacol. 2008;64:531–8.PubMedPubMedCentralCrossRefGoogle Scholar
  45. Derr RL, Ye X, Islas MU, et al. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009;27(7):1082–6.PubMedPubMedCentralCrossRefGoogle Scholar
  46. Dirlewanger M, Schneiter PH, Paquot N, et al. Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clin Nutr. 2000;19:29–34.PubMedCrossRefPubMedCentralGoogle Scholar
  47. Duarte JD, Cooper-DeHoff RM. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther. 2010;8(6):793–802.PubMedPubMedCentralCrossRefGoogle Scholar
  48. Dubé MP, Edmondson-Melançon H, Qian D, et al. Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. J Acquir Immune Defic Syndr. 2001;27(2):130–4.PubMedCrossRefPubMedCentralGoogle Scholar
  49. Dunder K, Lind L, Zethelius B, et al. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. BMJ. 2003;326:681.PubMedPubMedCentralCrossRefGoogle Scholar
  50. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201–7.CrossRefGoogle Scholar
  51. Eriksson JW, Jansson PA, Carlberg B, et al. Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the Mechanisms for the Diabetes Preventing Effect of Candesartan (MEDICA) Study. Hypertension. 2008;52(6):1030–7.PubMedCrossRefGoogle Scholar
  52. Fabris P, Floreani A, Tositti G, et al. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther. 2003;18:549–58.PubMedCrossRefPubMedCentralGoogle Scholar
  53. Fain JN. Effects of dexamethasone and 2-deoxy-D-glucose on fructose and glucose metabolism by incubated adipose tissue. J Biol Chem. 1964;239:958–62.PubMedGoogle Scholar
  54. Fardet L, Fève B. Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Drugs. 2014 Oct;74(15):1731–45. Scholar
  55. Fariss BL, Lutcher CL. Diphenylhdantoin-induced hyperglycemia and impaired insulin release: effect of dosage. Diabetes. 1971;20(3):177–81.PubMedCrossRefGoogle Scholar
  56. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003;46:1594–603.PubMedCrossRefPubMedCentralGoogle Scholar
  57. Fathallah N, Slim R, Larif S, et al. Drug-induced hyperglycaemia and diabetes. Drug Saf. 2015;38:1153–68.PubMedCrossRefGoogle Scholar
  58. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol. 1996;24:38–47.PubMedCrossRefPubMedCentralGoogle Scholar
  59. Fertig MK, Brooks VG, Shelton PS, et al. Hyperglycemia associated with olanzapine. J Clin Psychiatry. 1998;59:687–9.PubMedCrossRefGoogle Scholar
  60. Fisher JE, Smith RS, Lagrandeur R, et al. Gestational diabetes mellitus in women receiving beta-adrenergics and corticosteroids for threatened preterm delivery. Obstet Gynecol. 1997;90(6):880–3.PubMedCrossRefGoogle Scholar
  61. Friedman EA, Shyh TP, Beyer MM, et al. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol. 1985;5(3):196–202.PubMedCrossRefGoogle Scholar
  62. Friedrich A, Ludwig AK, Jauch-Chara K, et al. Oral contraception enhances growth hormone responsiveness to hyper- and hypoglycaemia. Diabet Med. 2012;29(3):345–50.PubMedCrossRefGoogle Scholar
  63. Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–84.PubMedCrossRefGoogle Scholar
  64. Garg AK. Hyperglycemia during replacement growth hormone therapy. J Pediatr. 1994;125:329.PubMedCrossRefGoogle Scholar
  65. Gòmez-Vera J, de Alarcón A, Jiménez-Mejías ME, et al. Hyperglycemia associated with protease inhibitors in HIV-1-infected patients. Clin Microbiol Infect. 2000;6:391–4.PubMedCrossRefGoogle Scholar
  66. Gonçalves P, Araújo JR, Martel F. Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Eur Neuropsychopharmacol. 2015;25(1):1–16. Scholar
  67. Gonwa T, Mendez R, Yang HC, Prograf Study Group. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation. 2005;75:1213–20.CrossRefGoogle Scholar
  68. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342:905–12.PubMedCrossRefGoogle Scholar
  69. Griffin ME, Marcucci MJ, Cline GW, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signalling cascade. Diabetes. 1999;48:1270–4.PubMedCrossRefGoogle Scholar
  70. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29:2728–9.PubMedCrossRefGoogle Scholar
  71. Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154:97–101.PubMedCrossRefGoogle Scholar
  72. Haas NB, Quirt I, Hotte S, McWhirter E, Polintan R, Litwin S, et al. Phase II trial of vorinostat in advanced melanoma. Investig New Drugs. 2014;32(3):526–34.CrossRefGoogle Scholar
  73. Hagg S, Joelsson L, Mjorndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry. 1998;59:294–9.PubMedCrossRefGoogle Scholar
  74. Hansen KB, Vilsboll T, Bagger JI, et al. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab. 2010;95:3309–17.PubMedCrossRefGoogle Scholar
  75. Hansen KB, Vilsboll T, Bagger JI, Holst JJ, Knop FK. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects. J Clin Endocrinol Metab. 2011;96:447–53.PubMedCrossRefGoogle Scholar
  76. Hansen KB, Vilsboll T, Bagger JI, et al. Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects. J Clin Endocrinol Metab. 2012;97:1363–70.PubMedCrossRefGoogle Scholar
  77. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157:975–81.PubMedCrossRefGoogle Scholar
  78. Henriksen JE, Alford F, Vaag A, et al. Intracellular skeletal muscle glucose metabolism is differentially altered by dexamethasone treatment of normoglycemic relatives of type 2 diabetic patients. Metabolism. 1999;48:1128–35.PubMedCrossRefGoogle Scholar
  79. Hershey DS, Bryant AL, Olausson J, et al. Hyperglycemic-inducing neoadjuvant agents used in treatment of solid tumors: a review of the literature. Oncol Nurs Forum. 2014;41:E343–54.PubMedCrossRefGoogle Scholar
  80. Hirst JA, Farmer AJ, Feakins BG, et al. Quantifying the effects of diuretics and beta-blockers on glycaemic control in diabetes mellitus – a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;79(5):733–43.PubMedPubMedCentralCrossRefGoogle Scholar
  81. Hoes JN, van der Goes MC, van Raalte DH, et al. Glucose tolerance, insulin sensitivity and beta-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis. 2011;70:1887–94.PubMedCrossRefGoogle Scholar
  82. Hoffman A, Kuntze JE, Baptista J, et al. Growth hormone replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:204–56.Google Scholar
  83. Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119–24.PubMedCrossRefGoogle Scholar
  84. Hwang IT. Efficacy and safety of growth hormone treatment for children born small for gestational age. Korean J Pediatr. 2014;57(9):379–83.PubMedPubMedCentralCrossRefGoogle Scholar
  85. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11:11–8.PubMedCrossRefGoogle Scholar
  86. Issekutz B Jr, Borkow I. Effect of glucagon and glucose load on glucose kinetics, plasma FFA, and insulin in dogs treated with methylprednisolone. Metabolism. 1973;22:39–49.PubMedCrossRefGoogle Scholar
  87. Jacob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two beta blocking agents on insulin sensitivity: the Carvedilol–Metoprolol Study. J Hypertens. 1996;14:489–94.PubMedCrossRefGoogle Scholar
  88. Jandeleit-Dahm KA, Tikellis C, Reid CM, et al. Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes. J Hypertens. 2005;23:463–73.PubMedCrossRefGoogle Scholar
  89. Jin JY, DuBois DC, Almon RR, et al. Receptor/gene-mediated pharmacodynamic effects of methylprednisolone on phosphoenolpyruvate carboxykinase regulation in rat liver. J Pharmacol Exp Ther. 2004;309:328–39.PubMedCrossRefGoogle Scholar
  90. Johannsson G, Rose’n T, Bengtsson B. Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol. 1997;47:571–81.CrossRefGoogle Scholar
  91. Johnston SS, Juday T, Esker S, et al. Comparative incidence and health care costs of medically attended adverse effects among US Medicaid HIV patients on atazanavir- or darunavir-based antiretroviral therapy. Value Health. 2013;16(2):418–25.PubMedCrossRefGoogle Scholar
  92. Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, et al. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes. 1989;38(5):562–8.PubMedCrossRefGoogle Scholar
  93. Kaplan SA, Shimizu CS. Effects of cortisol on amino acids in skeletal muscle and plasma. Endocrinology. 1963;72:267–72.PubMedCrossRefGoogle Scholar
  94. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602.PubMedCrossRefGoogle Scholar
  95. Khaleeli AA, Edwards RH, Gohil K, et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol. 1983;18:155–66.CrossRefGoogle Scholar
  96. Khoza S, Barner JC. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. Int J Clin Pharm. 2011;33:484–92.PubMedCrossRefGoogle Scholar
  97. Kim SY, Yoo C-G, Lee CT, et al. Incidence and risk factors of steroid-induced diabetes in patients with respiratory disease. J Korean Med Sci. 2011;26(2):264–7.PubMedPubMedCentralCrossRefGoogle Scholar
  98. Koh Y, Bidstrup H, Nichols DL. Niacin increased glucose, insulin, and C-peptide levels in sedentary nondiabetic postmenopausal women. Int J Womens Health. 2014;6:913–20.PubMedPubMedCentralCrossRefGoogle Scholar
  99. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22:841–52.PubMedCrossRefPubMedCentralGoogle Scholar
  100. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med. 2001;111:716–23.PubMedCrossRefPubMedCentralGoogle Scholar
  101. Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95:29–35.CrossRefGoogle Scholar
  102. Kraus-Friedmann N. Hormonal regulation of hepatic gluconeogenesis. Physiol Rev. 1984;64:170–259.PubMedCrossRefPubMedCentralGoogle Scholar
  103. Krebs M, Krssak M, Bernroider E, et al. Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. Diabetes. 2002;51:599–605.PubMedCrossRefPubMedCentralGoogle Scholar
  104. LaPlante KL, Mersfelder TL, Ward KE, et al. Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting. Pharmacotherapy. 2008;28:82–9.PubMedCrossRefPubMedCentralGoogle Scholar
  105. Lecocq FR, Mebane D, Madison LL. The acute effect of hydrocortisone on hepatic glucose output and peripheral glucose utilization. J Clin Invest. 1964;43:237–46.PubMedPubMedCentralCrossRefGoogle Scholar
  106. Létourneau G, Abdel-Baki A, Dubreucq S, Mahone M, Granger B. Hyperosmolar hyperglycemic state associated with ziprasidone treatment: a case report. J Clin Psychopharmacol. 2011;31:671–3.PubMedCrossRefPubMedCentralGoogle Scholar
  107. Levine M, Boyer EW, Pozner CN, et al. Assessment of hyperglycemia after calcium canne blocker overdoses involving diltiazem or verapamil. Crit Care Med. 2007;35(9):2071–5.PubMedCrossRefPubMedCentralGoogle Scholar
  108. Liegl U, Bogner JR, Goebel FD. Insulin-dependent diabetes mellitus following pentamidine therapy in a patient with AIDS. Clin Investig. 1994;72:1027–9.PubMedCrossRefPubMedCentralGoogle Scholar
  109. Liou YS, Chen HY, Tien L, et al. Antihypertensive drug use and new-onset diabetes in female patients with coronary artery disease: a population-based longitudinal cohort study. Medicine (Baltimore). 2015;94(36):e1495.CrossRefGoogle Scholar
  110. Lofberg E, Gutierrez A, Wernerman J, et al. Effects of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle. Eur J Clin Investig. 2002;32:345–53.CrossRefGoogle Scholar
  111. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev. 2014;4:CD006133.Google Scholar
  112. Luntz GR, Smith SG. Effect of isoniazid on carbohydrate metabolism in controls and diabetics. Br Med J. 1953;1:296–9.PubMedPubMedCentralCrossRefGoogle Scholar
  113. Lustman PJ, Freedland KE, Griffith LS, et al. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care. 2000;23:618–23.PubMedCrossRefPubMedCentralGoogle Scholar
  114. Lustman PJ, Clouse RE, Nix BD, et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:521–9.PubMedCrossRefPubMedCentralGoogle Scholar
  115. Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol. 2008;197:189–204.PubMedCrossRefPubMedCentralGoogle Scholar
  116. Makarovsky I, Markel G, Dushnitsky T, et al. Hydrazine – the space era agent. Isr Med Assoc J. 2008;10:302–6.PubMedPubMedCentralGoogle Scholar
  117. Maki KC, Ridker P, Brown W, et al. An assessment by the Statin Diabetes Safety Task Force: 2014 update. J Clin Lipidol. 2014;8:S17–29. Scholar
  118. Manish G, Keshav GK, Syed RM, et al. Isoniazid induced childhood diabetes: a rare phenomenon. J Basic Clin Pharm. 2015;6(2):74–6.PubMedPubMedCentralCrossRefGoogle Scholar
  119. Messerli FH, Bangalore S, Yao SS, et al. Cardioprotection with beta-blockers: myths, facts and Pascal’s wager. J Intern Med. 2009;266(3):232–41.PubMedCrossRefPubMedCentralGoogle Scholar
  120. Miyoshi H, Shulman GI, Peters EJ, et al. Hormonal control of substrate cycling in humans. J Clin Invest. 1988;81:1545–55.PubMedPubMedCentralCrossRefGoogle Scholar
  121. Mondal R, Nandi M, Tiwari A, et al. Diabetic ketoacidosis with L-asparaginase therapy. Indian Pediatr. 2011;48(9):735–6.PubMedPubMedCentralGoogle Scholar
  122. Moore MJ, Gong Y, Hou W, et al. Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide. Pharmacotherapy. 2014;34(11):1132–40.PubMedPubMedCentralCrossRefGoogle Scholar
  123. Muscogiuri G, Chavez AO, Gastaldelli A, et al. The crosstalk between insulin and renin angiotensin-aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention. Curr Vasc Pharmacol. 2008;6:301–12.PubMedCrossRefPubMedCentralGoogle Scholar
  124. Nada T, Nomura M, Koshiba K, et al. Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity. Arzneimittelforschung. 2007;57(11):698–704.PubMedPubMedCentralGoogle Scholar
  125. Nakamura M, Nagamine T. Severe hyperglycemia induced by olanzapine was improved with a recovery of insulin secretion after switching to risperidone and introducing insulin therapy. Intern Med. 2010;49:2635–7.PubMedCrossRefPubMedCentralGoogle Scholar
  126. Nielsen MF, Caumo A, Chandramouli V, et al. Impaired basal glucose effectiveness but unaltered fasting glucose release and gluconeogenesis during short-term hypercortisolemia in healthy subjects. Am J Physiol Endocrinol Metab. 2004;286:E102–10.PubMedCrossRefPubMedCentralGoogle Scholar
  127. Noto H, Goto A, Tsujimoto T, et al. Effect of calcium channel blockers on incidence of diabetes: a meta-analysis. Diabetes Metab Syndr Obes. 2013;6:257–61.PubMedPubMedCentralCrossRefGoogle Scholar
  128. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25:283–91.PubMedCrossRefPubMedCentralGoogle Scholar
  129. Ong K, Waters DD, Messig M, et al. Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study). Am J Cardiol. 2014;113:1593–8.PubMedCrossRefPubMedCentralGoogle Scholar
  130. Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97.PubMedPubMedCentralCrossRefGoogle Scholar
  131. Panetta JD, Gilani N. Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2009;30:597–602.PubMedCrossRefGoogle Scholar
  132. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006;354:1352–61.PubMedCrossRefGoogle Scholar
  133. Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism. 2011;60:1500–10.PubMedCrossRefGoogle Scholar
  134. Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabete Metab. 2006;32:539–46.PubMedCrossRefGoogle Scholar
  135. Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord. 2003;27(Suppl 3):S6–11.PubMedCrossRefGoogle Scholar
  136. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16(10):695–714.PubMedCrossRefGoogle Scholar
  137. Pieper JA. Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am J Health Syst Pharm. 2003;60:S9–14.PubMedGoogle Scholar
  138. Politi A, Poggio G, Margiotta A. Can amiodarone induce hyperglycaemia and hypertriglyceridaemia? Br Med J (Clin Res Ed). 1984;288(6413):285.CrossRefGoogle Scholar
  139. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta analysis. JAMA. 2011;305:2556–64.PubMedCrossRefGoogle Scholar
  140. Ranta F, Avram D, Berchtold S, et al. Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes. 2006;55:1380–90.PubMedCrossRefGoogle Scholar
  141. Reed ML, Merriam GR, Kargi AY. Adult growth hormone deficiency – benefits, side effects, and risks of growth hormone replacement. Front Endocrinol (Lausanne). 2013;4:64. eCollection 2013.CrossRefGoogle Scholar
  142. Reus S, Arroyo E, Boix V, et al. Lipodystrophy and hyperglycemia produced by protease inhibitors. An Med Interna. 2000;17(3):123–6.PubMedPubMedCentralGoogle Scholar
  143. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;360:565–71.CrossRefGoogle Scholar
  144. Rizos CV, Elisaf MS. Manidipine: a different dihydropyridine. World J Hypertens. 2011;1:3–6.CrossRefGoogle Scholar
  145. Rizos CV, Elisaf MS. Antihypertensive drugs and glucose metabolism. World J Cardiol. 2014;6(7):517–30.PubMedPubMedCentralCrossRefGoogle Scholar
  146. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab. 1982;54:131–8.PubMedCrossRefGoogle Scholar
  147. Roberson JR, Raju S, Shelso J, et al. Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50(6):1207–12.PubMedCrossRefGoogle Scholar
  148. Ronchi C, Epaminonda P, Cappiello V, et al. Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Investig. 2002;25(6):502–7.CrossRefGoogle Scholar
  149. Rooney DP, Neely RD, Cullen C, et al. The effect of cortisol on glucose/glucose-6-phosphate cycle activity and insulin action. J Clin Endocrinol Metab. 1993;77:1180–3.PubMedGoogle Scholar
  150. Rosei EA, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoreceptor antagonist with unique characteristics. Drugs. 2007;67:1097–10.CrossRefGoogle Scholar
  151. Rubin RR, Ma Y, Marrero DG, et al. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the Diabetes Prevention Program. Diabetes Care. 2008;31:420–6.PubMedCrossRefGoogle Scholar
  152. Ruzzin J, Wagman AS, Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia. 2005;48:2119–30.PubMedCrossRefGoogle Scholar
  153. Saad MJ, Folli F, Kahn JA, et al. Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest. 1993;92:2065–72.PubMedPubMedCentralCrossRefGoogle Scholar
  154. Salerno DM, Fifield J, Krejci J, Hodges M. Encainide-induced hyperglycemia. Am J Med. 1988;84(1):39–44.PubMedCrossRefGoogle Scholar
  155. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr. 2009;50(5):499–505. Scholar
  156. Samson SL. Long-term medical treatment of Cushing’s disease with pasireotide: a review of current evidence and clinical experience. Exp Clin Endocrinol Diabetes. 2014;122(8):445–50.PubMedCrossRefGoogle Scholar
  157. Samuelsson O, Hedner T, Berglund G, et al. Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Goteborg, Sweden. J Hum Hypertens. 1994;8:257–63.PubMedGoogle Scholar
  158. Sánchez-Barranco P. New onset of diabetes mellitus with ziprasidone: a case report. J Clin Psychiatry. 2005;66(2):268–9.PubMedCrossRefGoogle Scholar
  159. Saraya A, Yokokura M, Gonoi T, et al. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol. 2004;497:111–7.PubMedCrossRefGoogle Scholar
  160. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.PubMedPubMedCentralCrossRefGoogle Scholar
  161. Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low dose, diuretic based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med. 1998;158:741–51.PubMedCrossRefGoogle Scholar
  162. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabete Metab. 2004;30:498–505.PubMedCrossRefGoogle Scholar
  163. Schneiter P, Tappy L. Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans. Am J Phys. 1998;275(5 Pt1):E806–13.Google Scholar
  164. Shafi T, Appel LJ, Miller ER 3rd, et al. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension. 2008;52:1022–9. Scholar
  165. Shen M, Orwoll ES, Conte JE Jr, et al. Pentamidine-induced pancreatic beta-cell dysfunction. Am J Med. 1989;86:726–8.PubMedCrossRefGoogle Scholar
  166. Shen L, Shah BR, Reyes EM, et al. Role of diuretics, b blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ. 2013;347:f6745. Scholar
  167. Shepherd J, Blauw GJ, Murphy MG, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.PubMedCrossRefGoogle Scholar
  168. Short KR, Bigelow ML, Nair KS. Short-term prednisone use antagonizes insulin’s anabolic effect on muscle protein and glucose metabolism in young healthy people. Am J Physiol Endocrinol Metab. 2009;297:E1260–8.PubMedPubMedCentralCrossRefGoogle Scholar
  169. Skowronski R, Hollenbeck CB, Jaspan JB, Reaven GM, Landau C, Chen YD. Effect of nicotinic acid on plasma glucose concentration in normal individuals. Horm Metab Res. 1992;24(9):424–8.PubMedCrossRefGoogle Scholar
  170. Sridhar A, Sandeep Y, Krishnakishore C, et al. Fatal poisoning by isoniazid and rifampicin. Indian J Nephrol. 2012;22:385–7.PubMedPubMedCentralCrossRefGoogle Scholar
  171. Stone NJ, Robinson J, Lichtenstein AH, et al. 2014 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2014;129:S1–S45.CrossRefPubMedPubMedCentralGoogle Scholar
  172. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001–6.PubMedCrossRefGoogle Scholar
  173. Takasu N, Yamada T, Miura H, et al. Rifampicin-induced early phase hyperglycemia in humans. Am Rev Respir Dis. 1982;125(1):23–7.PubMedGoogle Scholar
  174. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol. 2005;16:3128–35.PubMedCrossRefGoogle Scholar
  175. Tham DM, Martin-McNully B, Wang YX, et al. Angiotiotensin II is associated with activation of NF-kB-mediated genes and downregulation of PPARS. Physiol Genomics. 2002;11(1):21–30.PubMedCrossRefGoogle Scholar
  176. Tollefson G, Lesar T. Nonketotic hyperglycemia associated with loxapine and amoxapine: case report. J Clin Psychiatry. 1983;44:347–8.PubMedGoogle Scholar
  177. Tourniaire J, Bajard L, Harfouch M, et al. Restoration of insulin sensitivity after correction of hypokalemia due to chronic tubulopathy in a diabetic patient. Diabete Metab. 1988;14(6):717–20.PubMedGoogle Scholar
  178. Tsuchiyama N, Ando H, Ota T, et al. Modulating effects of olanzapine on the development of diabetic ketoacidosis. Diabet Med. 2004;21:300–1.PubMedCrossRefGoogle Scholar
  179. Turnbow MA, Keller SR, Rice KM, et al. Dexamethasone down-regulation of insulin receptor substrate-1 in 3T3-L1 adipocytes. J Biol Chem. 1994;269:2516–20.PubMedGoogle Scholar
  180. US Food and Drug Administration (FDA). Drugs: FDA safety communication: important safety label changes to cholesterol-lowering statin drugs. 28 February 2012, Accessed 7 Jan 2014.
  181. Uzu T, Harada T, Sakaguchi M, et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract. 2007;105:c54–7.PubMedCrossRefGoogle Scholar
  182. van Raalte SH, Diamant M. Steroid diabetes: from mechanism to treatment? Neth J Med. 2014;72(2):62–72.PubMedGoogle Scholar
  183. van Raalte DH, Nofrate V, Bunck MC, et al. Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men. Eur J Endocrinol. 2010;162:729–35.PubMedCrossRefGoogle Scholar
  184. van Raalte DH, Brands M, van der Zijl NJ, et al. Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia. 2011a;54:2103–12.PubMedPubMedCentralCrossRefGoogle Scholar
  185. van Raalte DH, van Genugten RE, Linssen MM, et al. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care. 2011b;34:412–7.PubMedPubMedCentralCrossRefGoogle Scholar
  186. van Raalte DH, Diamant M, Ouwens DM, et al. Glucocorticoid treatment impairs microvascular function in healthy men in association with its adverse effects on glucose metabolism and blood pressure: a randomised controlled trial. Diabetologia. 2013a;56:2383–91.PubMedCrossRefGoogle Scholar
  187. van Raalte DH, Kwa KA, van Genugten RE, et al. Islet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance? Metabolism. 2013b;62:568–77.PubMedCrossRefPubMedCentralGoogle Scholar
  188. Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol. 2007;275:43–61.PubMedCrossRefGoogle Scholar
  189. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963–9.PubMedCrossRefGoogle Scholar
  190. Verrotti A, Manco R, Agostinelli S, et al. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia. 2010;51:268–73.PubMedCrossRefGoogle Scholar
  191. Vyas AK, Koster JC, Tzekov A, et al. Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J Biol Chem. 2010;285(47):36395–400.PubMedPubMedCentralCrossRefGoogle Scholar
  192. Wajngot A, Giacca A, Grill V, et al. The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. Proc Natl Acad Sci U S A. 1992;89:6035–9.PubMedPubMedCentralCrossRefGoogle Scholar
  193. Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy. J Am Coll Cardiol. 2013;61:148–52.PubMedCrossRefPubMedCentralGoogle Scholar
  194. Winter WE, Funahashi M, Koons J. Encainide-induced diabetes: analysis of islet cell function. Res Commun Chem Pathol Pharmacol. 1992;76(3):259–68.PubMedGoogle Scholar
  195. Wise JK, Hendler R, Felig P. Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man. J Clin Invest. 1973;52:2774–82.PubMedPubMedCentralCrossRefGoogle Scholar
  196. Wollheim CB, Kikuchi M, Renold AE, Sharp GW. The roles of intracellular and extracellular Ca++ in glucose-stimulated biphasic insulin release by rat islets. J Clin Investig. 1978;62(2):451–8.PubMedCrossRefGoogle Scholar
  197. Yamagishi S, Inagaki Y, Nakamura K, et al. Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharmacol. 2004;43(5):724–30.PubMedCrossRefGoogle Scholar
  198. Yamazaki M, Sato A, Takeda T, et al. Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-alpha treatment for chronic hepatitis C. Intern Med. 2010;49(5):403–7.PubMedCrossRefGoogle Scholar
  199. Yang Y, Wei RB, Xing Y, et al. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients. Metabolism. 2013;62(12):1858–66.PubMedCrossRefPubMedCentralGoogle Scholar
  200. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44.PubMedCrossRefPubMedCentralGoogle Scholar
  201. Yildirim SV, Azak E, Varan B, et al. Unusual and early hyperglycemia following amiodarone infusion in two infants. Pediatr Cardiol. 2005;26(5):715–6.PubMedCrossRefPubMedCentralGoogle Scholar
  202. Zhang R, Packard BA, Tauchi M, et al. Glucocorticoid regulation of preproglucagon transcription and RNA stability during stress. Proc Natl Acad Sci U S A. 2009;106:5913–8.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Systems Medicine; Unit of Endocrinology, Diabetes and MetabolismS. Giovanni Calibita Fatebenefratelli Hospital, University of Rome Tor VergataRomeItaly

Personalised recommendations